• Diagnosis of postural tachycardia syndrome using the following criteria:
  • Orthostatic heart rate increment greater than or equal to 30 beats per minute (bpm) within 5 minutes of head-up tilt.
  • Symptoms of orthostatic intolerance. These include weakness, lightheadedness, blurred vision, nausea, palpitations, and difficulty with concentration and thinking.
• Both criteria must be fulfilled.

• Pregnant or lactating women
• Presence of failure of other organ systems or systemic illness that could affect autonomic function or the patient's ability to cooperate with the study
• Hypothyroidism or hyperthyroidism
• Clinically significant coronary artery disease
• Medications that could interfere with autonomic testing
• Previous treatment with pyridostigmine for POTS. Patients must not have taken pyridostigmine in the past month

• Subjects with hereditary eye disease.
• Subjects with a family history of hereditary eye disease.
• Subjects without hereditary eye disease and no family history of hereditary eye disease who would serve as a control in specific case-control experiments.
• Ability to understand and willingness to sign the informed consent documents.

• Unable or unwilling to sign or understand the informed consent documents.
• Unwilling to participate in the research.
• Unwilling to allow genetic testing.
• Unwilling to allow samples to be sent to other institutional for testing.
• Not meeting the inclusion criteria.

• Over the age of 18
• non-CF Bronchiectasis
• Nontuberculosis Mycobacteria (NTM)

• Under the age of 18
• CF Bronchiectasis

Inclusion Criteria

• Male or female
• Has inflammatory disease thought to be autoimmune, infectious, or paraneoplastic
  • Controls will not have an inflammatory disease
• All ages are being enrolled
• Must be able to give informed consent or have an appropriate representative available to do so.

Exclusion Criteria

• Institutionalized (i.e., Federal Medical Prison)
• Allergy to lidocaine, bupivacaine, and/or epinephrine for skin punch biopsy only

• Male and female patient volunteers ages 8 and up who are suspicious for thyroid cancer.
• Group of patients who have palpable and sonographically detectable lymph nodes or non-thyroidal neck masses and are referred to Radiology Department for or Endocrinology for FNAB.
• Pregnant women will be included because there is no significant risk with our experiment.
• Patients 18 and up who were previously diagnosed with thyroid cancer and treated with thyroidectomy and recently diagnosed as having recurrence nodes on thyroid bed or on their neck. 

• Because thyroid cancer is rare under the age of 8 years, children younger than this age are excluded from the study.     
• Having FANB or surgical biopsy on thyroid in less than two weeks for thyroid nodule detection group.     
• Having FNAB or surgical biopsy on cervical lymph nodes or non- thyroidal masses for this group of patients.   

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 12/20/23. Questions regarding updates should be directed to the study team contact.

Inclusion Criteria
•200 patients undergoing primary THA/TKA for osteoarthritis:

• Adult (18 years old or greater).
• Primary diagnosis is osteoarthritis (OA).
• Must be primary total joint arthroplast  .

Inclusion Criteria - 200 patients undergoing revision THA/TKA for infection with culture positive Staphylococcus aureus:

• Adult (18 years old or greater).
• Index surgical procedure was for OA .
• Patient must have metal-on-UHMWPE bearing surface.
• At least 2 positive intraoperative cultures depicting Staphylococcus aureus.
• Have clinical picture consistent with infection, including, but not limited to:
  • Patient symptomatic;
  • Increased laboratory values (WBC, ESR, CRP);
  • Positive aspiration;
  • Necessitates revision surgery in the opinion of the consulting surgeon.

Inclusion Criteria - 200 patients undergoing revision THA/TKA for infection with culture positive Staphylococcus epidermidis:

• Adult (18 years old or greater).
• Index surgical procedure was for OA .
• Patient must have metal-on-UHMWPE bearing surface.
• At least 2 positive intraoperative cultures depicting Staphylococcus epidermis.
• Have clinical picture consistent with infection, including, but not limited to:
  • Patient symptomatic;
  • Increased laboratory values (WBC, ESR, CRP);
  • Positive aspiration;
  • Necessitates revision surgery in the opinion of the consulting surgeon.Inc

Inclusion Criteria - 200 patients undergoing revision THA/TKA for culture negative infection:

• Adult (18 years old or greater).
• Index surgical procedure was for OA .
• Patient must have metal-on-UHMWPE bearing surface.
• Negative cultures at time of surgery, but has one of following:
  • Sinus tract (as determined by consulting surgeon);
  • Gross purulence (as determined by consulting surgeon);
  • Acute inflammation (as determined by consulting pathologist);
  • Symptomatic patient with elevated inflammatory markers (WBC, CRP, ESR);
  • Necessitates revision surgery in the opinion of the consulting surgeon.

Inclusion Criteria - 200 patients undergoing revision THA/TKA for culture negative osteolysis:

• Adult (18 years old or greater).
• Index surgical procedure was for OA .
• Patient must have metal-on-UHMWPE bearing surface.
• Evidence of osteolysis on either serial plain radiographs (AP / cross-table lateral) or advanced imaging (CT or MRI with artifact minimization).
• Occurs in the absence of infection:
  • Patient asymptomatic;
  • Normal laboratory values (WBC, ESR, CRP);
  • Negative aspiration;
  • Negative cultures at time of surgery;
  • Necessitates revision surgery in the opinion of the consulting surgeon.
• 100 patients undergoing revision THA for metal reaction.
• Adult (18 years old or greater).
• Index surgical procedure was for OA .
• Patient must have metal-on-metal bearing surface.
• Soft tissue mass noted on MRI or US.
• Periprosthetic pathologic tissue reveals chronic inflammation with perivascular lymphocytic aggregates.
• Occurs in absence of infection:     
  • Patient asymptomatic;
  • Normal laboratory values (WBC, ESR, CRP);
  • Negative aspiration;
  • Negative cultures at time of surgery;
  • Necessitates revision surgery in the opinion of the consulting surgeon.

Inclusion Criteria - 100 patients undergoing revision TKA for flexion instability:

• Adult (18 years old or greater).
• Index surgical procedure was for OA .
• Patient must have metal-on-UHMWPE bearing surface.
• Evidence of instability on either serial plain radiographs (AP / cross-table lateral) or advanced imaging (CT or MRI with artifact minimization).
• Occurs in the absence of infection:
  • Patient asymptomatic;
  • Normal laboratory values (WBC, ESR, CRP);
  • Negative aspiration;
  • Negative cultures at time of surgery;
  • Necessitates revision surgery in the opinion of the consulting surgeon.

Inclusion Criteria - 100 patients undergoing revision TKA for arthrofibrosis:

• Adult (18 years old or greater).
• Index surgical procedure was for OA.
• Patients must have metal-on-PE bearing surface.
• Evidence of arthrofibrosis on clinical exam and/or plain radiographs.
• Occurs in the absence of infection:
  • Patient asymptomatic;
• Normal laboratory values (WBC, ESR, CRP);
• Negative aspiration;
• Negative cultures at time of surgery;
• Necessitates revision surgery in the opinion of the consulting surgeon.

Exclusion Criteria
•200 patients undergoing primary THA/TKA for osteoarthritis:

• Revision surgery.
• History of malignancy in operative extremity.
• Steroid use after index surgical procedure.
• Presence of a condition interfering with the ability to provide informed consent.

Exclusion Criteria - 200 patients undergoing revision THA/TKA for infection with culture positive Staphylococcus aureus:

• Any diagnosis other than osteoarthritis as reason for index surgical procedure (i.e., inflammatory arthritis, posttraumatic arthritis, septic arthritis, osteonecrosis, etc.).
• History of malignancy in operative extremity.
• Steroid use after index surgical procedure.
• Presence of a condition interfering with the ability to provide informed consent.

Exclusion Criteria - 200 patients undergoing revision THA/TKA for infection with culture positive Staphylococcus epidermidis:

• Any diagnosis other than osteoarthritis as reason for index surgical procedure (i.e., inflammatory arthritis, posttraumatic arthritis, septic arthritis, osteonecrosis, etc.) .
• History of malignancy in operative extremity.
• Steroid use after index surgical procedure.
• Presence of a condition interfering with the ability to provide informed consent.

Exclusion Criteria - 200 patients undergoing revision THA/TKA for culture negative infection:

• Any diagnosis other than osteoarthritis as reason for index surgical procedure (i.e., inflammatory arthritis, posttraumatic arthritis, septic arthritis, osteonecrosis, etc.) 
• History of malignancy in operative extremity
• Steroid use after index surgical procedure
• Presence of a condition interfering with the ability to provide informed consent.

Exclusion Criteria - 200 patients undergoing revision THA/TKA for culture negative osteolysis:

• Any diagnosis other than osteoarthritis as reason for index surgical procedure (i.e., inflammatory arthritis, posttraumatic arthritis, septic arthritis, osteonecrosis, etc.) .
• History of malignancy in operative extremity.
• Steroid use after index surgical procedure.
• Presence of a condition interfering with the ability to provide informed consent.

Exclusion Criteria - 100 patients undergoing revision THA for metal reaction:

• Any diagnosis other than osteoarthritis as reason for index surgical procedure (i.e., inflammatory arthritis, posttraumatic arthritis, septic arthritis, osteonecrosis, etc.) .
• History of malignancy in operative extremity.
• Steroid use after index surgical procedure.
• Presence of a condition interfering with the ability to provide informed consent.

Exclusion Criteria - 100 patient undergoing revision TKA for instability:

• Any diagnosis other than osteoarthritis as reason for index surgical procedure (i.e., inflammatory arthritis, posttraumatic arthritis, septic arthritis, osteonecrosis, etc.).
• History of malignancy in operative extremity.
• Steroid use after index surgical procedure.
• Presence of a condition interfering with the ability to provide informed consent.

Exclusion Criteria - 100 patients undergoing revision TKA for arthrofibrosis:

• History of malignancy in operative extremity.
• Steroid use after index surgical procedure.
• Presence of a condition interfering with the ability to provide informed consent.

Patients presenting with an incipient clinical diagnosis for FSGS/MCD or MN or pediatric participants not previously biopsied, with a clinical diagnosis for FSGS/MCD or MN meeting the following inclusion criteria:

• Documented urinary protein excretion ≥500 mg/24 hours or spot protein: creatinine ratio equivalent at the time of diagnosis or within 3 months of the screening/eligibility visit.
• Scheduled renal biopsy

• Prior solid organ transplant
• A clinical diagnosis of glomerulopathy without diagnostic renal biopsy
• Clinical, serological or histological evidence of systemic lupus erythematosus (SLE) as defined by the ARA criteria. Patients with membranous in combination with SLE will be excluded because this entity is well defined within the International Society of Nephrology/Renal Pathology Society categories of lupus nephritis, and frequently overlaps with other classification categories of SLE nephritis (68)
• Clinical or histological evidence of other renal diseases (Alport, Nail Patella, Diabetic Nephropathy, IgA-nephritis, monoclonal gammopathy (multiple myelomas), genito-urinary malformations with vesico-urethral reflux or renal dysplasia)
• Known systemic disease diagnosis at time of enrollment with a life expectancy less than 6 months
• Unwillingness or inability to give a comprehensive informed consent
• Unwillingness to comply with study procedures and visit schedule
• Institutionalized individuals (e.g., prisoners)

Controls

• Healthy male volunteers
• Non-pregnant, non-breastfeeding female volunteers
• 18-70 years old
• Able to provide written informed consent before participating in the study
• Able to communicate adequately with the investigator and to comply with the requirements for the entire study

Additional inclusion criteria for patients

• Symptoms of dyspepsia with rapid gastric emptying by scintigraphy

Patients and controls

• Abdominal surgery other than appendectomy, cholecystectomy, tubal ligation or hysterectomy
• Clinical evidence of significant:
  • Ccardiovascular 
  • Respiratory 
  • Renal 
  • Hepatic 
  • Gastrointestinal
  • Hematological 
  • Neurological 
  • Psychiatric 
  • Other disease that may interfere with the objectives of the study and/or pose safety concerns 
• Medications that may alter gastrointestinal motility, e.g., antipressants, alpha adrenergic agonists, calcium channel or b blockers. 
• Stable dose of thyroxine will be permitted. 
• If it is clinically safe, antidepressants (e.g., nortrptyline, amitryptyline), which are often used at low doses to delay gastric emptying and/or reduce visceral sensitivity, will be discontinued in patients before the study
• Patients who have taken any investigational medications within the past 30 days
• Pregnant or breast-feeding females

Exclusion criteria for controls only

• Current symptoms of a functional gastrointestinal disorder assessed by questionnaire

• Patients undergoing percutaneous nephrolithotomy or ureteroscopy for treatment of symptomatic renal or proximal ureteral stones without evidence of pyelonephritis will be included. 
• Control patients will be those individuals undergoing percutaneous, ureteroscopic or nephrectomy for non-stone related indications.

• Pregnant patients are not eligible for this protocol, and would not generally have invasive stone removal procedures. 
• All women of child bearing age will have pregnancy testing as part of their routine clinical care.

• Age birth-100 years, male or female, any race/ethnicity
• Potential participant shall have a confirmed diagnosis of a mitochondrial disease or a suspected diagnosis based on a review of clinical history by a Mitochondrial Disease Biobank working group member using the clinical criteria listed in the table below
• Selected participants shall have at least two documented conditions contained within the minor clinical criteria
  • Minor Criteria
    • Symptoms compatible with a mitochondrial defect
    • Smaller numbers of RRF or widespread electron microscopy abnormalities of mitochondria
    • Antibody-based demonstration of an mito defect or residual activity of an mito complex 20%–30% in a tissue, 30%–40% in a cell line, or 30%–40% in >2 tissues
    • Fibroblast ATP synthesis rates 2–3 SD below mean, or fibroblasts unable to grow in galactose media
    • Nuclear or mtDNA mutation of probable pathogenicity
    • One or more metabolic indicators of impaired metabolic function
• OR one condition in the major criteria with evidence of a condition in the minor criteria, will be considered for inclusion of a participant of appropriate age
  • Major Criteria
    • Multi-systemic symptoms characteristic of mito disorder
    • Progressive clinical course with episodes of exacerbation
    • A family history strongly indicative of an mtDNA mutation
    • Exclusion of other metabolic or non-metabolic disorders
    • >2% ragged red fibers (RRF) in skeletal muscle
    • Cytochrome c oxidase negative fibers (>2-5%) or residual activity of a mito complex <20% in a tissue; <30% in a cell line, or <30% in >2 tissues
    • Fibroblast ATP synthesis rates >3 SD below mean
    • Nuclear or mtDNA mutation of undisputed pathogenicity
• 1st-degree relatives of affected participants (described above) are also invited to participate in the project.
• In addition, samples from participants with one of the following mitochondrial disease diagnosis will be included:
  • Alpers’ progressive sclerosing poliodystrophy 
  • Barth syndrome 
  • CPEO 
  • Dominant optic atrophy
  • Friedriech’s Ataxia
  • Hereditary paraganglioma 
  • Hereditary spastic paraplegia 
  • Kearns-Sayre syndrome Leber hereditary optic neuroretinopathy
  • Leigh and Leigh-like Syndrome 
  • MELAS 
  • MERRF
  • NARP 
  • Pearson syndrome 
  • Wolfram syndrome 
  • Mitochondrial fatty acid oxidation disorder 
  • Urea cycle defect

• Unwilling to provide informed consent
• Unwilling to consent to providing biospecimens to be stored in the biobank for an indefinite amount of time and to be used in future research studies of as yet unknown design
• Does not have a diagnosis of mitochondrial disease or clinical symptoms that are indicative of a potential mitochondrial disease as determined by a chart review by at least one Individualized Medine Biobank for Mitochondrial Disease working-group member

• Patients hospitalized with acute heart failure and/or STEMI/NSTEMI

• Hemoglobin less than 10, active cancer, amyloidosis

• Patients and subjects 18 years or older and in stable medical condition.
• Patients at low risk for TB infection:
  • Being born in a low-incidence TB area, and low risk for contact with TB cases (i.e., no prior work or history of staying in a potentially TB transmissible area such as inpatient hospital facility, jail or prison, or nursing home); or
  • Who also are tested for job screening purposes or prior to initiation of immunosuppressive therapy.
• Patients at intermediate to high risk for TB infection: Recent TST or IGRA testing, or clinical indication for either TST or IGRA testing (i.e., Contacts of TB cases, foreign-born subjects without other risk factors for TB infection, patients on immunosuppressive therapy, chronic medical conditions at risk of TB infections, healthcare worker screening, etc.). We will also include patients with history of prior discordant TST and QuantiFERON TB Gold/In-Tube™ results.
• Patient with recent diagnosis of culture-proven TB infection or on treatment for active TB, pending final culture results.
• Signed written informed and HIPAA consent.

• Patients younger than 18 years old.
• Patients unable to perform the study protocol.
• Patients unwilling or unable to give written informed consent.

• Consented participants in IRB study 489-04, Genetic Epidemiology of B-Cell Lymphoproliferative Disorders.
• History of MBL if not in study 489-04.

• Is unable to understand English and/or complete the informed consent form.

Eligibility last updated 8/20/21. Questions regarding updates should be directed to the study team contact.

• Patients (heterozygous for germline SDH mutations (subunits B, C or D) undergoing surgery for confirmed primary or metastatic PGL of abdomen, pelvis, mediastinum, neck or head. 
• Tumor size should be consistent for greater than 1 cc viable tumor tissue after retention of clinical pathology specimen.

• Be ≥ 18 years of age
• Have been admitted to hospital
• Have a signed informed consent by participant or surrogate/representative
• Have a local diagnosis (confirmed or suspected) of influenza, or of a targeted non-influenza viral respiratory infection*, resulting in (or extending a previous) hospitalization
  • A list of targeted non-influenza respiratory viruses is maintained on the INSIGHT website.

• Current imprisonment, or compulsory detention (involuntary incarceration) for treat of a psychiatric or physical illness.

• Patients age 0-100 with a clinically diagnosed heritable channelopathy or cardiomyopathy (the proband). 
• Relatives of the proband  ≥ 18 years old who are mutation negative and/or disease negative, to serve as controls. 
• Note of clarification: Only children with a clinically diagnosed heritable channelopathy or cardiomyopathy are eligible to participate in this study.  If the relative of a proband is a child without the heritable channelopathy or cardiomyopathy, that child is not eligible to participate.

• Patients with allergy to subcutaneous lidocaine, bupivicaine, or epinephrine.  
• Relatives of a proband that are < 18 years of age who are mutation negative and/or disease-negative. 
  • In other words, children are only eligible for this study if they themselves have a heritable channelopathy or cardiomyopathy; they are not eligible to serve as controls.

Inclusion Criteria:

Selection for care center participation will be based on the following criteria:

• Demonstrate a commitment to providing the necessary resources and time for testing and implementing changes to improve care at the care center.
• Identify a multidisciplinary team to attend semi-annual 2-day learning sessions.
• Resolve to make appropriate changes in the structure of how care is monitored and delivered to patients.
• Agree to regularly collect and transmit clinical measurements pertinent to the aims of the network to be included in the data registry.
• Agree to participate in periodic conference calls
• Commit to paying a registration fee to participate and receive needed support.

Patients

• Patient recruitment will be conducted by the care centers. 
  • Care center physicians or trained staff included on the care center IRB protocol will be responsible for identifying and recruiting potential patient participants. 
• All patients ages 0-17 years of age with a clinical diagnosis of IBD, regardless of gender, race or ethnicity will be recruited to participate in the study. 

Patients

• Post-colectomy UC patients.

1. Diagnosis and/or management of AAOCA at a CHSS member institution from January 1, 1998 forward
2. Male or female age 0-30 years at time of diagnosis
3. If surgical repair:
   1. Performed from January 1, 1998 to study initiation (January 20, 2009) for retrospective subjects
   2. Performed from January 21, 2009 forward for prospectively identified subjects
   3. Completed operative note
4. Structurally normal heart or with small, hemodynamically insignificant lesion, including:
   1. Patent ductus arteriosus 
   2. Atrial septal defect 
   3. Ventricular septal defect
   4. Mild pulmonic valvar stenosis 
   5. Bicuspid aortic valve without aortic stenosis
5. Parental/guardian permission (informed consent, and authorization as applicable) 
6. Subject consent, and authorization as applicable if ≥ 18 years of age and if appropriate, child assent for the observational/questionnaire portion of the study.

1. Anomalous coronary from the pulmonary artery, coronary artery atresia, or other coronary artery anomalies (e.g., coronary-cameral fistula, coronary aneurysms, myocardial bridging)
2. Hemodynamically significant structural heart disease, except as outlined above.

Inclusion Criteria  

• Age 18 to 85 years old.
• Equal number of males and females.
• Participants recruited to three experimental groups:
  • Class I-II heart failure patients;
  • Class III-IV heart failure patients;
  • Age, BMI and sex matched healthy control subjects.

Exclusion Criteria  

• Pacemaker dependent.
• If they currently smoke.
• If they are allergic to the CT contrast material.
• If participating in an aim of the study in which an esophageal balloon catheter will be used, subjects will be excluded if:
  • They are allergic to latex; or
  • If they have a history of nose bleeds.                      

Subjects enrolled in

• Subjects enrolled in the Mayo Alzheimer’s Disease Research Center (IRB# 712-98) or other dementia related studies in our program or seen in the Mayo neurodegenerative disease clinics.

• Subjects on anti-coagulant therapy will be excluded.
• Pregnant women will be excluded.          

Inclusion Criteria

• Age 18 years or older
• Able to provide informed consent
• Family willing/able to provide consent for unsolicited volunteers
• Has a surgical procedure performed by staff in the Division of Cardiovascular Surgery at Mayo Clinic Rochester
• Has a Mayo Clinic ID

Exclusion Criteria

• Institutionalized (i.e., Federal Medical Prison)

Inclusion Criteria

• A history of documented atrial fibrillation who undergo cardiac surgery for valvular heart disease or coronary artery disease with concomitant MAZE procedure
• A history of documented atrial fibrillation including post-operative AF undergoing cardiac surgery without MAZE procedure
• A history of atrial fibrillation undergoing cardiac surgery (controls)
• Heart transplant recipients with AF or without AF (controls)
• All above willing to donate surgically removed atrial tissue to the study

• Subjects currently without a specimen in the cardiovascular disease repository
• Subjects diagnosed with Heart failure from 2006 to present who reside in the 5 county area

Subjects meeting the troponin criteria, reside in the 7-county area, and currently do not have a DNA specimen in the Cardiovascular Disease Specimen Repository or any of the following studies IRB #s 632-01, 2346-02, 1194-05, and 07-0060760. 

• Subjects who have undergone PCI or CABG from 2002 through August 2013 
• Those who undergo PCI or CABG
• Subjects with atrial fibrillation identified in the retrospective study IRB #11-003629

• Not eligible for venipuncture

• Subjects must have a malignancy 
• Under the age of 21

• All normal healthy adults 
• Adults with interstitial lung disease

• Individuals who are or may become claustrophobic during the MR exam. 
• Individuals who have medical devices or implanted foreign metal objects for which MR imaging is contraindicated

• Between the ages of 13 and 25 years
• Participation in the Mayo Comprehensive Pediatric Pain Rehabilitation Center
• Ability to understand written English to complete standardized assessment measures
• 18 years of age and a parent of a child participating in the Mayo Comprehensive Pediatric Pain Rehabilitation Center.

• Cognitive deficits or language difficulties that would invalidate standardized  assessment

• Potential surgical candidate to treat primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), ADPKD (Autosomal Dominant Polycystic Kidney Disease), ARPKD (Autosomal Recessive Polycystic Kidney Disease), liver resection or gallbladder disease.

• None.

Group IA

• Patients with open elbow procedures or trauma which have resulted in arthrofibrosis of the elbow joint  

Group IB

• Patients with normal motion  

Group IIA 

• Patients with established shoulder contractures limiting ADL’s 

Group IIB

• Normal patients 

Group IIIA 

• Patients with knee arthrofibrosis after TKA  

Group IIIB

• Patients without contracture after TKA

• Age less than 18 years
• History of infection in operative extremity
• History of malignancy in operative extremity
• Presence of a condition

• Patients age 0-100 yrs. with clinically diagnosed hypoplastic left heart syndrome (HLHS) undergoing planned surgical repair and unaffected adult biological parents and/or siblings.

• Subjects with allergy to subcutaneous lidocaine, bupivicaine, or epinephrine.